Sagimet Biosciences (SGMT) Earnings Date & Reports

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

SGMT is expected to report earnings to rise 57.14% to -87 cents per share on August 25

Sagimet Biosciences SGMT Stock Earnings Reports

Q2'25

Est.

$-0.88

Q1'25

Beat

by $0.15

Q4'24

Missed

by $0.01

Q3'24

Beat

by $0.10

Q2'24

Beat

by $0.25

The last earnings report on May 08 showed earnings per share of -56 cents, beating the estimate of -70 cents. With 6.04M shares outstanding, the current market capitalization sits at 153.57M.

View a ticker or compare two or three

Compare

SGMT